Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. 1989

W Kirch, and H D Janisch, and E E Ohnhaus, and A van Peer
First Medical Department, Christian-Albrechts-University, Kiel, F.R.G.

The pharmacokinetic interaction between the gastrointestinal motility-stimulating substance cisapride and the H2-antagonist cimetidine was examined in 8 healthy volunteers (25 +/- 2 years of age). Steady-state kinetics of both substances were investigated after separate 1-week treatments of oral cisapride, 10 mg t.i.d., cimetidine, 400 mg t.i.d., and the two drugs combined. Cimetidine increased the cisapride peak plasma concentration from 58 +/- 25 ng/ml to 84 +/- 19 ng/ml (p = 0.01) and AUC0-24 from 509 +/- 289 ng/ml.h to 738 +/- 148 ng/ml.h (p = 0.02). Cisapride shortened the time to the peak concentration of cimetidine from 1.3 +/- 0.6 h to 0.6 +/- 0.2 h (p = 0.005) and reduced the cimetidine AUC0-24 from 11.0 +/- 2.3 micrograms/ml.h to 9.0 +/- 2.0 micrograms/ml.h (p = 0.05). It is concluded that cimetidine inhibits cisapride metabolism, whereas cisapride enhances the gastrointestinal absorption of cimetidine.

UI MeSH Term Description Entries
D008297 Male Males
D010880 Piperidines A family of hexahydropyridines.
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D020117 Cisapride A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed) Propulsid,R-51619,R 51619,R51619

Related Publications

W Kirch, and H D Janisch, and E E Ohnhaus, and A van Peer
June 1984, The Journal of pharmacology and experimental therapeutics,
W Kirch, and H D Janisch, and E E Ohnhaus, and A van Peer
February 1986, Journal of clinical psychopharmacology,
W Kirch, and H D Janisch, and E E Ohnhaus, and A van Peer
September 1980, Lancet (London, England),
W Kirch, and H D Janisch, and E E Ohnhaus, and A van Peer
September 1980, Lancet (London, England),
W Kirch, and H D Janisch, and E E Ohnhaus, and A van Peer
January 1981, Acta clinica Belgica,
W Kirch, and H D Janisch, and E E Ohnhaus, and A van Peer
July 1988, Lancet (London, England),
W Kirch, and H D Janisch, and E E Ohnhaus, and A van Peer
November 1979, European journal of clinical pharmacology,
W Kirch, and H D Janisch, and E E Ohnhaus, and A van Peer
January 1981, Lancet (London, England),
W Kirch, and H D Janisch, and E E Ohnhaus, and A van Peer
March 1981, Lancet (London, England),
W Kirch, and H D Janisch, and E E Ohnhaus, and A van Peer
August 1990, Hepato-gastroenterology,
Copied contents to your clipboard!